Treatment Landscape for Older Men With Metastatic Hormone‐Sensitive Prostate Cancer in the United States
Three in 10 older men with mHSPC received no systemic treatment. Although there was a gradual uptake of ARPIs, monotherapy with ADT was still highly prevalent, suggesting the integration of intensified treatment is still suboptimal. Targeted interventions are necessary to enhance guideline adherence among older and frail men with mHSPC.
Authors
- Nethra Sambamoorthi
- Bo Zhou (ORCID: https://orcid.org/0000-0001-9440-6295)
- Matthew J. Korn
- Usha Sambamoorthi (ORCID: https://orcid.org/0000-0001-8311-1360)
- Rafia S. Rasu (ORCID: https://orcid.org/0000-0002-6485-9629)
- Amit D. Raval (ORCID: https://orcid.org/0000-0001-8265-8612)
- Niculae Constantinovici
- Natasha Littleton
- Yifan Zhang (ORCID: https://orcid.org/0000-0002-0283-0468)
Institutions
- University of North Texas (US)
- Bayer (United States) (US)
- University of North Texas Health Science Center (US)
- Bayer (Switzerland) (CH)
- Bayer (Germany) (DE)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1002/cam4.71176
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- California Department of Public Health
- University of Southern California
- Bayer HealthCare
- Centers for Disease Control and Prevention
- University of California, San Francisco
- National Cancer Institute